Trinity Biotech plc Total Liabilities
Trinity Biotech plc total liabilities. Based on the latest financial reports, Trinity Biotech plc (TRIB) has total liabilities worth $177.15 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TRIB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Trinity Biotech plc (1993–2025)
Total liabilities of Trinity Biotech plc from 1993 to 2025. This chart illustrates how Trinity Biotech plc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Trinity Biotech plc to see how much of total assets are deployed in long-term investments.
Trinity Biotech plc Competitors by Total Liabilities
The table below lists competitors of Trinity Biotech plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brera Holdings PLC Class B Ordinary Shares
NASDAQ:BREA
|
USA | $6.30 Million |
|
Instinct Bio Technical Company Holdings Inc. Ordinary Shares
NASDAQ:BIOT
|
USA | $912.54K |
|
Nacon S.A.
PA:NACON
|
France | €245.10 Million |
|
Artemis Resources Ltd
AU:ARV
|
Australia | AU$4.19 Million |
|
Zephyr Minerals Ltd
V:ZFR
|
Canada | CA$250.96K |
|
Nvni Group Limited Ordinary Shares
NASDAQ:NVNI
|
USA | $517.01 Million |
|
Industronics Bhd
KLSE:9393
|
Malaysia | RM43.30 Million |
|
Game Your Game, Inc. Common Stock
NASDAQ:GYGY
|
USA | $4.52 Million |
Liability Composition Analysis (1993–2025)
This chart breaks down Trinity Biotech plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Trinity Biotech plc's balance sheet.
Liquidity & Leverage Metrics
Trinity Biotech plc Total Liabilities Ratios Explained
Trinity Biotech plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Trinity Biotech plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Trinity Biotech plc (1993–2025)
The table below shows the annual total liabilities of Trinity Biotech plc from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $177.15 Million | +27.93% |
| 2024-12-31 | $138.47 Million | +66.06% |
| 2023-12-31 | $83.38 Million | -11.56% |
| 2022-12-31 | $94.28 Million | -20.92% |
| 2021-12-31 | $119.21 Million | -10.11% |
| 2020-12-31 | $132.62 Million | +4.95% |
| 2019-12-31 | $126.36 Million | +17.89% |
| 2018-12-31 | $107.18 Million | -15.88% |
| 2017-12-31 | $127.42 Million | -9.55% |
| 2016-12-31 | $140.87 Million | -2.90% |
| 2015-12-31 | $145.07 Million | +216.30% |
| 2014-12-31 | $45.87 Million | +5.50% |
| 2013-12-31 | $43.48 Million | +55.12% |
| 2012-12-31 | $28.03 Million | +38.97% |
| 2011-12-31 | $20.17 Million | +2.96% |
| 2010-12-31 | $19.59 Million | -63.11% |
| 2009-12-31 | $53.10 Million | -16.51% |
| 2008-12-31 | $63.60 Million | -19.62% |
| 2007-12-31 | $79.13 Million | -3.34% |
| 2006-12-31 | $81.87 Million | +60.58% |
| 2005-12-31 | $50.98 Million | +46.97% |
| 2004-12-31 | $34.69 Million | -8.30% |
| 2003-12-31 | $37.83 Million | +43.51% |
| 2002-12-31 | $26.36 Million | +28.60% |
| 2001-12-31 | $20.50 Million | +68.18% |
| 2000-12-31 | $12.19 Million | -45.40% |
| 1999-12-31 | $22.32 Million | -26.58% |
| 1998-12-31 | $30.40 Million | +73.71% |
| 1997-12-31 | $17.50 Million | +525.00% |
| 1996-12-31 | $2.80 Million | +64.71% |
| 1995-12-31 | $1.70 Million | -5.56% |
| 1994-12-31 | $1.80 Million | 0.00% |
| 1993-12-31 | $1.80 Million | -- |
About Trinity Biotech plc
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually tr… Read more